When the Senate Committee on Appropriations marked up the fiscal 2019 spending bill, NIH came out ahead—$2 billion ahead.
In recent years, Vinay Prasad, a young hematologist–oncologist at Oregon Health and Science University, has emerged as a premier critic of new directions in cancer medicine.
In May 2018, President Trump announced his plan to lower drug prices. “We will have tougher negotiation, more competition, and much lower prices at the pharmacy counter. And it will start to take effect very soon,” he promised. The plan is outlined in a 40-page document by the U.S. Department of Health and Human Services titled “American Patients First—The Trump Administration Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Cost.” (1)
An NCI-sponsored trial showed that up to 70 percent of women with hormone receptor-positive, HER2-negative, axillary lymph node-negative breast cancer would not benefit from chemotherapy.
St. Jude Children's Research Hospital is expanding its international outreach program with an initial investment of $100 million to improve childhood cancer survival rates worldwide.
After six months of listening and observing the functioning of MD Anderson Cancer Center, Peter Pisters announced changes in the cancer center's organizational chart.
As they reach for surgical tools, gynecologists vastly underestimate the probability that their patients have undiagnosed uterine cancers, a study by Yale University researchers found.
Relying largely on maturing data from the European trials of screening for prostate cancer, the U.S. Preventive Services Task Force has given a better grade—a “C”—to screening for prostate cancer.
Bristol-Myers Squibb and Flatiron Health announced a three-year collaboration to advance methodologies for the curation of real-world data for cancer research and to develop regulatory-grade information.
The Stephenson Cancer Center at the University of Oklahoma May 2 announced that it has received Cancer Center designation from NCI.
